# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001842952-24-000083
Filing Date
2024-09-23
Accepted
2024-09-23 07:33:19
Documents
60
Period of Report
2024-09-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | cntx-20240923.htm iXBRL | 8-K | 36819
2 | EX-10.1 | bioatla-contexttherapeutic.htm | EX-10.1 | 363747
3 | EX-99.1 | a2024-09x23xxbcabxxexclusi.htm | EX-99.1 | 22038
4 | EX-99.2 | a2024sept-contextxcorpde.htm | EX-99.2 | 48236
8 |  | a2024sept-contextxcorpde001.jpg | GRAPHIC | 54250
9 |  | a2024sept-contextxcorpde002.jpg | GRAPHIC | 216291
10 |  | a2024sept-contextxcorpde003.jpg | GRAPHIC | 114785
11 |  | a2024sept-contextxcorpde004.jpg | GRAPHIC | 101291
12 |  | a2024sept-contextxcorpde005.jpg | GRAPHIC | 98157
13 |  | a2024sept-contextxcorpde006.jpg | GRAPHIC | 66619
14 |  | a2024sept-contextxcorpde007.jpg | GRAPHIC | 79102
15 |  | a2024sept-contextxcorpde008.jpg | GRAPHIC | 114586
16 |  | a2024sept-contextxcorpde009.jpg | GRAPHIC | 97261
17 |  | a2024sept-contextxcorpde010.jpg | GRAPHIC | 77503
18 |  | a2024sept-contextxcorpde011.jpg | GRAPHIC | 67590
19 |  | a2024sept-contextxcorpde012.jpg | GRAPHIC | 115441
20 |  | a2024sept-contextxcorpde013.jpg | GRAPHIC | 116597
21 |  | a2024sept-contextxcorpde014.jpg | GRAPHIC | 85637
22 |  | a2024sept-contextxcorpde015.jpg | GRAPHIC | 110140
23 |  | a2024sept-contextxcorpde016.jpg | GRAPHIC | 96879
24 |  | a2024sept-contextxcorpde017.jpg | GRAPHIC | 131168
25 |  | a2024sept-contextxcorpde018.jpg | GRAPHIC | 98143
26 |  | a2024sept-contextxcorpde019.jpg | GRAPHIC | 88053
27 |  | a2024sept-contextxcorpde020.jpg | GRAPHIC | 67202
28 |  | a2024sept-contextxcorpde021.jpg | GRAPHIC | 107376
29 |  | a2024sept-contextxcorpde022.jpg | GRAPHIC | 111050
30 |  | a2024sept-contextxcorpde023.jpg | GRAPHIC | 104904
31 |  | a2024sept-contextxcorpde024.jpg | GRAPHIC | 89392
32 |  | a2024sept-contextxcorpde025.jpg | GRAPHIC | 93186
33 |  | a2024sept-contextxcorpde026.jpg | GRAPHIC | 103674
34 |  | a2024sept-contextxcorpde027.jpg | GRAPHIC | 128512
35 |  | a2024sept-contextxcorpde028.jpg | GRAPHIC | 89665
36 |  | a2024sept-contextxcorpde029.jpg | GRAPHIC | 91793
37 |  | a2024sept-contextxcorpde030.jpg | GRAPHIC | 67616
38 |  | a2024sept-contextxcorpde031.jpg | GRAPHIC | 108317
39 |  | a2024sept-contextxcorpde032.jpg | GRAPHIC | 125819
40 |  | a2024sept-contextxcorpde033.jpg | GRAPHIC | 110281
41 |  | a2024sept-contextxcorpde034.jpg | GRAPHIC | 105173
42 |  | a2024sept-contextxcorpde035.jpg | GRAPHIC | 96418
43 |  | a2024sept-contextxcorpde036.jpg | GRAPHIC | 97194
44 |  | a2024sept-contextxcorpde037.jpg | GRAPHIC | 64481
45 |  | a2024sept-contextxcorpde038.jpg | GRAPHIC | 83165
46 |  | a2024sept-contextxcorpde039.jpg | GRAPHIC | 65259
47 |  | a2024sept-contextxcorpde040.jpg | GRAPHIC | 59557
48 |  | a2024sept-contextxcorpde041.jpg | GRAPHIC | 51676
49 |  | a2024sept-contextxcorpde042.jpg | GRAPHIC | 96156
50 |  | image_0.jpg | GRAPHIC | 46410
51 |  | image_1.jpg | GRAPHIC | 36786
| Complete submission text file | 0001842952-24-000083.txt |  | 6396590

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | cntx-20240923.xsd | EX-101.SCH | 1937
6 | XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | cntx-20240923_lab.xml | EX-101.LAB | 24372
7 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | cntx-20240923_pre.xml | EX-101.PRE | 14143
62 | EXTRACTED XBRL INSTANCE DOCUMENT | cntx-20240923_htm.xml | XML | 3001

Mailing Address 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103
Business Address 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103 267-225-7416
Context Therapeutics Inc. (Filer) CIK: 0001842952 (see all company filings)

EIN.: 863738787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40654 | Film No.: 241314642
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)